SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clover Health is trending as traders speculate on a potential strategic partnership with Humana, fueled by recent job postings referencing Clover's software platform. Community sentiment remains mixed, balancing long-term optimism regarding the company's SaaS potential and Medicare Advantage growth against frustration over stagnant price action and perceived market manipulation.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders speculate on imminent positive guidance updates following the company's recent healthcare conference appearances and anticipation of upcoming Phase 2 NSCLC trial data. While the stock has seen significant momentum, community sentiment remains focused on potential institutional accumulation and the expectation that the company's solid tumor platform and clinical milestones will drive long-term value.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike shares are rallying sharply as traders react to record-breaking quarterly results and increased demand for AI-powered cybersecurity, with management emphasizing that AI-driven threats are accelerating the need for modern security platforms. While the stock's significant valuation premium continues to trigger debate among traders, sentiment is bolstered by bullish analyst price target hikes and positive read-throughs from industry conferences.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox shares are trending due to a sharp selloff following an earnings report that featured a revenue guidance withdrawal and concerns regarding monetization. While some traders are viewing the decline as an opportunity to buy the dip, others remain bearish, citing ongoing regulatory scrutiny, past controversies, and skepticism about the company's path to profitability.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as traders speculate on a potential recovery following a recent share price decline, with many discussing the company's pivot toward AI infrastructure and its upcoming re-entry into the Euro STOXX 50 index. While bulls highlight strategic partnerships and potential index-driven buying as catalysts for a rally, others express frustration with the stock's stagnant performance and ongoing concerns regarding market manipulation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Markets are volatile as traders weigh concerns over a potential slowdown in AI development against bullish rhetoric from Donald Trump, who continues to influence price action through social media. Discussion remains fragmented between bears highlighting macro headwinds like rising 10-year Treasury yields and oil prices, and bulls betting on liquidity-driven pumps ahead of the upcoming Federal Reserve meeting.

The Elmet Group Co. engages in the provision of precision-engineered components. The firm offers its products and solutions to aerospace, defense, industrial, medical, semiconductor, electronics, energy industry and also the government. It operates through the Critical Materials Components and Engineered Microwave Products business divisions. The company was founded on September 13, 2024 and is headquartered in Portland, ME.

Elmet Group Co. (The)

The Elmet Group

The Elmet Group is trending due to the company securing a massive investment and defense contract from the U.S. government to expand domestic tungsten production. Community sentiment is largely bullish, with traders emphasizing the stock's potential as a critical defense play, though some skeptics remain concerned about the financial structure and potential dilution.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is seeing increased attention as its Waymo unit launches fully driverless, public robotaxi services in Las Vegas. While some traders are focused on this autonomous expansion and AI infrastructure developments, others are debating broader concerns regarding elevated capital expenditures and market volatility.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as traders react to a sharp decline in AI and semiconductor stocks following calls from industry leaders to pace frontier AI development. While bearish sentiment is high due to these safety concerns and rising Treasury yields, market participants remain divided, with many debating the impact of the AI slowdown narrative versus the long-term infrastructure investment cycle.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne shares are trending as traders weigh its attractive valuation and AI-driven growth potential against broader sector volatility and lackluster price action compared to cybersecurity peers. The community remains divided between those viewing the stock as an undervalued takeover candidate with a strong balance sheet and those frustrated by the asset's underperformance relative to competitors like CrowdStrike and Palo Alto Networks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining in pre-market trading.read more...

Why Did TRAW Stock Slump 28% After Hours?

Equity

Traws is delaying a planned human study of its lead flu treatment, tivoxavir marboxil, after feedback from a UK regulator.

Do Not Ignore this Rally

The market is currently witnessing a rare phenomenon: a synchronized breakout across the small-cap and emerging growth sectors. While mega-cap tech grabs the headlines, the real alpha is being generated by innovators in energy, space, and biotech. As we head into the closing bell and the crucial after-hours session, momentum is building in names that are fundamentally shifting their industries. $INTC, $RXT, $BB, $TRAW, $XERI, $RDW

A Hantavirus Update Has Sent This Nano-Cap Biotech Stock Surging Today – Here’s Why Retail Sees Potential 20x Gains

Traws Pharma, which develops antiviral drugs, said it plans to advance potential clinical candidates for the treatment of hantavirus infections.

Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?

The company announced the completion of enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.read more...

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials ChemDiv Extends CMC Services Collaboration for...

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. Dover...

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Reported GAAP EPS of -$0.16 down -45.45% YoY

Traws Pharma faces significant challenges including a clinical hold on its lead program, absence of revenue, and potential future liquidity constraints necessitating additional financing to support operations beyond early 2027.

Traws Pharma is progressing its lead influenza candidate toward MHRA resubmission while securing potential financing of up to $50 million and expanding its platform capabilities into other emerging viral threats.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Traws Pharma Inc.

Bullish Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Stocktwits

The Fed's rate decision comes Wednesday at 2PM ET. What do you think happens?

Feed

News

Sentiment

Earnings

Fundamentals

Info

TRAW Traws Pharma Inc.

Fundamentals

Latest TRAW News